PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC
-
Cholesterol drug may block melanoma spread in High-Risk patients
Prevention OngoingThis study tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvastatin or a…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Prevention
Last updated Jun 01, 2026 17:55 UTC
-
Facebook group aims to boost skin checks in young melanoma families
Knowledge-focused OngoingThis study looks at whether a private Facebook group can encourage young adults (ages 18-39) diagnosed with early-stage melanoma and their close family members to perform more skin exams and use better sun protection. About 1,160 participants will join either a melanoma-focused o…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:57 UTC
-
Melanoma survivors: how does immunotherapy affect your daily life?
Knowledge-focused OngoingThis study looks at side effects and overall well-being in people who have had melanoma and are now getting immunotherapy to prevent the cancer from coming back. Researchers will track side effects and ask participants about their quality of life, depression, and fatigue for up t…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 03, 2026 12:08 UTC